Anti-metatype antibodies in immunoassays

In this review anti-metatype antibodies are described invoking new principles in immunoassay development. Anti-metatype antibodies are immunological reagents specific for the conformation of the liganded antibody active site which do not interact with bound ligand or unliganded antibody. Relationships between anti-metatype antibody reactivity and the ligand-induced conformational state of monoclonal antibodies are reviewed with emphasis on the fluorescein hapten as a small molecule model system. One characteristic result of the interaction of anti-metatype antibodies with liganded antibodies is a significant delay in the dissociation rate (k₂) of the ligand bound within the primary immune complex. The latter is an important consideration for assay development. Polyclonal and monoclonal anti-metatype antibody reagents are characterized in terms of their differential effects on the ligand dissociation rate. Anti-metatype antibody reactivity is further discussed in terms of protein-protein specificity patterns and relative interactions with idiotype-family members, structural derivatives, and site-specific mutants. Incorporation of principles inherent in the anti-metatype concept and their application to assay development are summarized.Abbreviations D₂O deuterium oxide - Fab 50 kd antibody fragment containing V_HC_H1 + V_LC_L domains - FITC(I) fluorescein isothiocyanate (isomer I) - Fv 26 kd fragment of the antibody molecule containing the variable domains of the H and L chains - Ig immunoglobulin - IgG immunoglobulin G with a mol. wt. of 150 kd. - IgM immunoglobulin M with a mol. wt. of 10⁶d - Id idiotype - Ka antibody affinity (k₁/k₂) in M^–1 - k₁ second order rate of ligand association in M^–1s^–1 - k₂ first order rate of ligand dissociation in s^–1 - K_D dissociation constant or the reciprocal of the affinity constant (1/Ka) - Mab monoclonal antibody - Met metatype - NMR nuclear magnetic resonance - SCA single chain Fv derivative containing a synthetic linker between the two variable domains - V_H variable domain of the antibody H chain - V_L variable domain of the antibody L chain